1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Market Access in the EU5 – a comparative overview

Market Access in the EU5 – a comparative overview

  • August 2013
  • -
  • Firstword Pharma
  • -
  • 107 pages




The sustained and challenging economic environment in the EU has impacted – and is impacting - pharmaceutical companies as never before. But success is still possible for those that understand the new operating environment and can navigate through the changes.

With health expenditure under scrutiny throughout the EU, spending on drugs has been targeted as a key area for cost savings. Now, gaining EU marketing authorisation from the EMA for a new drug is no longer a guarantee of commercial success, and companies must respond to national market conditions where a product must prove not just clinical effectiveness but show real economic advantage and benefits.

A high value market

The main pharmaceutical markets of the EU still rank among the world’s best for innovative medicines. The pharmaceutical market value of the top 5 EU markets at ex factory prices exceeded €101,627 million in 2011. Despite health payer encouragement to use generic alternatives, generic drugs accounted for relatively little of the value, for example 30.6% in Germany but only 9.7% in Italy. The challenge facing each country in controlling its drugs bill is illustrated by per capita pharmaceutical expenditure: In France this was €608 while in Spain in was €299.

Drug pricing and reimbursement policies evolve

Countries vary in their response to tackling the funding of drugs and strategies to control the market through drug pricing and reimbursement policies continue to develop. The willingness to act has gone beyond clinician encouragement, voluntary codes and pricing deals. A raft of regulatory changes in Germany, France and the UK will see fundamental changes to drug pricing and reimbursement assessment. For the Pharma industry it’s tight, and it’s getting tighter.

Essential market access data and insights are now available in this new report

Using secondary source information, much of which is not available in English, this report, Market Access in the EU5 – a comparative overview, provides a detailed snapshot of the current environment and trends that are influencing market access in the five leading EU markets: France, Germany, Italy, Spain and the UK. A comprehensive overview provides valuable insights and tables of key indicators allowing easy “compare and contrast” assessment. This is followed by country specific sections examining at a national level the current status and future changes to pharmaceutical regulation, pricing, reimbursement in the context of health, demographic and economic trends.






The report answers practical questions:


Who are the key decision makers for pricing and reimbursement in the major EU markets?
What are the forthcoming changes with regard to drug pricing systems?
What criteria are assessed for reimbursement decisions and how do these vary country to country?
Does inclusion in the national formulary mean a drug will automatically be available to patients throughout the country?
Are the rules for pricing and reimbursement any different for generics, compared with those for innovative medicines?
Are demographic or economic trends having a real effect on pharmaceutical spending?







Drill down into the issues that are shaping the markets and evaluate:



The introduction of formal medico-economic assessments in autumn 2013 in France
The Amendment to the German AMNOG act and the impact it may have on new innovative medicines
Why companies would be wise to engage with regional government in Italy
The role managed entry agreements play in Spain
The impact of the introduction of value based pricing in the UK in 2014







Content Highlights


Executive summary

The leading EU pharmaceutical markets
Background information: demographic and economic indicators
Payer-led, economy driven healthcare
Regulatory authorities/European Medicines Agency
Evolution in pricing and reimbursement

France

Market access considerations
Regulatory authority: Agence Nationale de Securitié du Médicament (ANSM)
Pricing and reimbursement
Market environment
Demographic and economic indicators
Trends in health and pharmaceutical spending
Healthcare provision

Germany

Market access considerations
Regulatory authority: Federal Institute for Drugs and Medicinal Products (BfArM)
Pricing and reimbursement
Market environment
Demographic and economic indicators
Trends in health and pharmaceutical spending
Healthcare provision


Italy

Market access considerations
Regulatory authority: Agenzi Italiana del Farmaco (AIFA)
Pricing and reimbursement
National regulation, regional implementation
Market environment
Demographic and economic indicators
Trends in health and pharmaceutical spending
Healthcare provision




Spain

Market access considerations
Regulatory authority: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Pricing and reimbursement
Market environment
Demographic and economic indicators
Trends in health and pharmaceutical spending
Healthcare provision



UK

Market access considerations
Regulatory authority: Medicines and Healthcare Regulatory Agency (MHRA)
Pricing and reimbursement
Market environment
Demographic and economic indicators
Trends in health and pharmaceutical spending
Healthcare provision


Table Of Contents

Market Access in the EU5 - a comparative overview
1.Executive summary
1.1.The leading EU pharmaceutical markets
1.2.Background information: demographic and economic indicators
1.3.Payer-led, economy driven healthcare
1.4.Regulatory authorities/European Medicines Agency
1.5.Evolution in pricing and reimbursement


2.France
2.1.Market access considerations
2.2.Regulatory authority: Agence Nationale de Securitie du Medicament (ANSM)
2.3.Pricing and reimbursement
2.4.Market environment
2.5.Demographic and economic indicators
2.6.Trends in health and pharmaceutical spending
2.7.Healthcare provision


3.Germany
3.1.Market access considerations
3.2.Regulatory authority: Federal Institute for Drugs and Medicinal Products (BfArM)
3.3.Pricing and reimbursement
3.4.Market environment
3.5.Demographic and economic indicators
3.6.Trends in health and pharmaceutical spending
3.7.Healthcare provision


4.Italy
4.1.Market access considerations
4.2.Regulatory authority: Agenzi Italiana del Farmaco (AIFA)
4.3.Pricing and reimbursement
4.4.National regulation, regional implementation
4.5.Market environment
4.6.Demographic and economic indicators
4.7.Trends in health and pharmaceutical spending
4.8.Healthcare provision


5.Spain
5.1.Market access considerations
5.2.Regulatory authority: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
5.3.Pricing and reimbursement
5.4.Market environment
5.5.Demographic and economic indicators
5.6.Trends in health and pharmaceutical spending
5.7.Healthcare provision


6.UK
6.1.Market access considerations
6.2.Regulatory authority: Medicines and Healthcare Regulatory Agency (MHRA)
6.3.Pricing and reimbursement
6.4.Market environment
6.5.Demographic and economic indicators
6.6.Trends in health and pharmaceutical spending
6.7.Healthcare provision

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.